{"id":"W4310859181","doi":"10.1016/j.jtocrr.2022.100444","title":"First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Merck Sharp and Dohme; Ministère de la Santé et des Services sociaux; Merck","keywords":"Pembrolizumab; Medicine; Carboplatin; Internal medicine; Chemotherapy; Oncology; Confidence interval; Retrospective cohort study; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008555872,0.0001703813,0.0001881541,0.0006045598,0.0003564265,0.0006777605,0.0002848249,0.0002661412,0.001211756],"category_scores_gemma":[0.002819742,0.0001854491,0.0002585674,0.001243077,0.0002096499,0.0005714366,0.0005619306,0.0003196214,0.0002431758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009792499,"about_ca_system_score_gemma":0.000662252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008602858,"about_ca_topic_score_gemma":0.01374007,"domain_scores_codex":[0.999206,0.0002185934,0.0001328611,0.0001953639,0.0001668868,0.00008040866],"domain_scores_gemma":[0.9958793,0.0003580934,0.002961364,0.0001604891,0.0003001438,0.0003405762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00007806333,0.00002738222,0.9978667,0.00001116954,0.00002998454,0.00003483044,0.00005466121,0.00006887934,0.00005379822,0.000009490616,0.0001617194,0.001603213],"study_design_scores_gemma":[0.00002100259,0.0001655153,0.9976183,0.00001885123,0.00004308132,0.0004389214,0.0002247498,0.000341332,0.0001984682,0.00002489691,0.0008994152,0.000005374952],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973265,0.0003070836,0.00009856582,0.0000773514,0.00000303044,0.00002139097,0.001718074,0.000004910515,0.0004431327],"genre_scores_gemma":[0.9973223,0.0001765318,0.0001632224,0.00004549768,0.000009127913,0.00002377278,0.002100319,0.000002055492,0.0001572314],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008602858,"threshold_uncertainty_score":0.01710558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1758482435059359,"score_gpt":0.5244882499617058,"score_spread":0.3486400064557699,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}